217 related articles for article (PubMed ID: 21896903)
21. Kinetic Study of Laboratory Mutants of NDM-1 Metallo-β-Lactamase and the Importance of an Isoleucine at Position 35.
Marcoccia F; Bottoni C; Sabatini A; Colapietro M; Mercuri PS; Galleni M; Kerff F; Matagne A; Celenza G; Amicosante G; Perilli M
Antimicrob Agents Chemother; 2016 Apr; 60(4):2366-72. PubMed ID: 26856833
[TBL] [Abstract][Full Text] [Related]
22. Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.
Papp-Wallace KM; Taracila MA; Smith KM; Xu Y; Bonomo RA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4428-38. PubMed ID: 22687511
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility of beta-lactamase to core amino acid substitutions.
Petrosino JF; Baker M; Palzkill T
Protein Eng; 1999 Sep; 12(9):761-9. PubMed ID: 10506286
[TBL] [Abstract][Full Text] [Related]
24. Insight into stereochemistry of a new IMP allelic variant (IMP-55) metallo-β-lactamase identified in a clinical strain of Acinetobacter baumannii.
Shakibaie MR; Azizi O; Shahcheraghi F
Infect Genet Evol; 2017 Jul; 51():118-126. PubMed ID: 28336429
[TBL] [Abstract][Full Text] [Related]
25. Amino acid substitutions in a variant of IMP-1 metallo-beta-lactamase.
Iyobe S; Kusadokoro H; Ozaki J; Matsumura N; Minami S; Haruta S; Sawai T; O'Hara K
Antimicrob Agents Chemother; 2000 Aug; 44(8):2023-7. PubMed ID: 10898670
[TBL] [Abstract][Full Text] [Related]
26. Understanding the determinants of substrate specificity in IMP family metallo-β-lactamases: the importance of residue 262.
Pegg KM; Liu EM; George AC; LaCuran AE; Bethel CR; Bonomo RA; Oelschlaeger P
Protein Sci; 2014 Oct; 23(10):1451-60. PubMed ID: 25131397
[TBL] [Abstract][Full Text] [Related]
27. Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
Marchiaro P; Tomatis PE; Mussi MA; Pasteran F; Viale AM; Limansky AS; Vila AJ
Antimicrob Agents Chemother; 2008 Jun; 52(6):2250-2. PubMed ID: 18362187
[TBL] [Abstract][Full Text] [Related]
28. Role of Residues W228 and Y233 in the Structure and Activity of Metallo-β-Lactamase GIM-1.
Skagseth S; Carlsen TJ; Bjerga GE; Spencer J; Samuelsen Ø; Leiros HK
Antimicrob Agents Chemother; 2016 Feb; 60(2):990-1002. PubMed ID: 26643332
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of AmpC beta-lactamase through a destabilizing interaction in the active site.
Trehan I; Beadle BM; Shoichet BK
Biochemistry; 2001 Jul; 40(27):7992-9. PubMed ID: 11434768
[TBL] [Abstract][Full Text] [Related]
30. Identification of residues critical for metallo-beta-lactamase function by codon randomization and selection.
Materon IC; Palzkill T
Protein Sci; 2001 Dec; 10(12):2556-65. PubMed ID: 11714924
[TBL] [Abstract][Full Text] [Related]
31. Amino acid residues that contribute to substrate specificity of class A beta-lactamase SME-1.
Majiduddin FK; Palzkill T
Antimicrob Agents Chemother; 2005 Aug; 49(8):3421-7. PubMed ID: 16048956
[TBL] [Abstract][Full Text] [Related]
32. The sequence-activity relationship between metallo-β-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure.
Liu EM; Pegg KM; Oelschlaeger P
Antimicrob Agents Chemother; 2012 Dec; 56(12):6403-6. PubMed ID: 23006757
[TBL] [Abstract][Full Text] [Related]
33. Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.
Drawz SM; Taracila M; Caselli E; Prati F; Bonomo RA
Protein Sci; 2011 Jun; 20(6):941-58. PubMed ID: 21404358
[TBL] [Abstract][Full Text] [Related]
34. Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC.
Guillon H; Tande D; Mammeri H
Antimicrob Agents Chemother; 2011 Sep; 55(9):4443-6. PubMed ID: 21746958
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.
Osano E; Arakawa Y; Wacharotayankun R; Ohta M; Horii T; Ito H; Yoshimura F; Kato N
Antimicrob Agents Chemother; 1994 Jan; 38(1):71-8. PubMed ID: 8141584
[TBL] [Abstract][Full Text] [Related]
36. Role of Asp104 in the SHV beta-lactamase.
Bethel CR; Hujer AM; Hujer KM; Thomson JM; Ruszczycky MW; Anderson VE; Pusztai-Carey M; Taracila M; Helfand MS; Bonomo RA
Antimicrob Agents Chemother; 2006 Dec; 50(12):4124-31. PubMed ID: 16982784
[TBL] [Abstract][Full Text] [Related]
37. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.
Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G
J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307
[TBL] [Abstract][Full Text] [Related]
38. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
39. Mutation S115T in IMP-Type Metallo-β-Lactamases Compensates for Decreased Expression Levels Caused by Mutation S119G.
Zhang CJ; Faheem M; Dang P; Morris MN; Kumar P; Oelschlaeger P
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31718049
[TBL] [Abstract][Full Text] [Related]
40. A drug-resistant β-lactamase variant changes the conformation of its active-site proton shuttle to alter substrate specificity and inhibitor potency.
Soeung V; Lu S; Hu L; Judge A; Sankaran B; Prasad BVV; Palzkill T
J Biol Chem; 2020 Dec; 295(52):18239-18255. PubMed ID: 33109613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
